Case 15-2008: A 55-year-old man with an elevated prostate-specific antigen level and early-stage prostate cancer

New England Journal of Medicine

Volumn 358, Issue 20, 2008, Pages 2161-

  Barry, Michael J ^a,b   Kaufman, Donald S ^a,b   Wu, Chin Lee ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; ENZYME INHIBITOR; FINASTERIDE; STEROID 5ALPHA REDUCTASE;

ADULT; ARTICLE; BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; EARLY CANCER; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HUMAN; HUMAN TISSUE; MALE; NEEDLE BIOPSY; NOCTURIA; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATECTOMY; URGE INCONTINENCE; URINALYSIS; BLOOD; CANCER STAGING; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; DRUG ANTAGONISM; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATE TUMOR; URINE RETENTION;

ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE 5-ALPHA-REDUCTASE; URINARY RETENTION;

EID: 43549122613     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcpc0707057     Document Type: Article

References (30)

1. Young RH, Srigley JR, Amin MB, et al. Tumors of the prostate gland, seminal vesicles, male urethra, and penis. In: Atlas of tumor pathology. Series 3. Fascicle 28. Washington, DC: Armed Forces Institute of Pathology, 2000:111-99.
2. DF Gleason Classification of prostatic carcinoma. Cancer Chemother Rep 50 1966 125 128
3. DF Gleason G Mellinger Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111 1974 58 64
4. DF Gleason Histologic grading of prostate cancer: a perspective. Hum Pathol 23 1992 273 279
5. SE Lerner ML Blute EJ Bergstrahlh DG Bostwick JT Eickholt H Zincke Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol 156 1996 137 143
6. Grading of prostatic carcinoma. In: Humphrey PA. Prostate pathology. Chicago: ASCP Press, 2003:138-374.
7. MR Cupp DG Bostwick RP Myers JE Oesterling The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol 153 1995 1543 1548
8. DD Dietrick JE McNeal TA Stamey Core cancer length in ultrasound-guided systematic sextant biopsies: a preoperative evaluation of prostate cancer volume. Urology 45 1995 987 992
9. JI Epstein PC Walsh M Carmichael Brendler CBl Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271 1994 368 374
10. AM O'Connor AG Mulley Jr. JE Wennberg Standard consultations are not enough to ensure decision quality regarding preference-sensitive options. J Natl Cancer Inst 95 2003 570 571
11. TD Denberg TV Melhado JF Steiner Patient treatment preferences in localized prostate carcinoma: the influence of emotion, misconception, and anecdote. Cancer 107 2006 620 630
12. Arias E. United States life tables, 2003. National vital statistics reports. Vol. 54. No. 14. Hyattsville, MD: National Center for Health Statistics, 2006. (DHHS publication no. (PHS) 2006-1120.)
13. Sox HC. Interactive textbook on clinical symptom research: tools for decision making. Bethesda, MD: National Institutes of Health, 2006. (Accessed April 18, 2008, at http://symptomresearch.nih.gov/chapter_14/Part_1/sec8/chspt1s8pg1.htm .)
14. M McNaughton Collins DF Ransohoff MJ Barry Serendipity strikes again: early detection of prostate cancer. JAMA 278 1997 1516 1519
15. L Cheng C Poulos C-X Pan Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens. J Urol 174 2005 898 902
16. B Chappell J McLoughlin Technical considerations when obtaining and interpreting prostatic biopsies from men with suspicion of early prostate cancer. BJU Int 95 2005 1141 1145
17. AV D'Amico M-H Chen KA Roehl WJ Catalona Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 2004 125 135
18. AV D'Amico AA Renshaw B Sussman MH Chen Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294 2005 440 447
19. PC Albertsen JA Hanley J Fine 20-Year outcomes following conservative management of clinically localized prostate cancer. JAMA 293 2005 2095 2101
20. C Parker D Muston J Melia S Moss D Dearnaley A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 94 2006 1361 1368
21. G Draisma R Boer SJ Otto Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95 2003 868 878
22. PC Albertsen JA Hanley GH Barrows Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 97 2005 1248 1253
23. JH Pinthus M Witkos N Fleshner Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome. J Urol 176 2006 979 984
24. RM Martin D Gunnell F Hamdy D Neal A Lane J Donovan Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era. J Urol 176 2006 439 449
25. L Klotz Active surveillance for prostate cancer: for whom? J Clin Oncol 23 2005 8165 8169
26. DC Miller SB Gruber BK Hollenbeck JE Montie JT Wei Incidence of initial local therapy among men with lower risk prostate cancer in the United States. J Natl Cancer Inst 98 2006 1134 1141
27. AV D'Amico MJ Barry Prostate cancer prevention and finasteride. J Urol 176 2006 2010 2012
28. C Warlick BJ Trock P Landis JI Epstein HB Carter Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 98 2006 355 357
29. IM Thompson PJ Goodman CM Tangen The influence of finasteride on the development of prostate cancer. N Engl J Med 349 2003 215 224
30. TB Sheridan HB Carter W Wang PB Landis JI Epstein Change in prostate cancer grade over time in men followed expectantly for stage T1c disease. J Urol 179 2008 901 905